Company intelligence / Profile preview
Obsidian Therapeutics
Cambridge, Massachusetts, USAobsidiantx.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
OBX-115, the company's lead clinical program, has shown promising activity in patients with immune checkpoint inhibitor-resistant advanced melanoma. The FDA granted Fast Track Designation for OBX-115 for the treatment of advanced melanoma.
- Therapeutic areas
- Oncology
- Modalities
- Cell therapyGene therapyEngineered TIL (tumor infiltrating lymphocyte) therapies
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Request access →03
Partnerships
Bristol Myers SquibbVertex Pharmaceuticals
Beyond the preview
Go deeper on Obsidian Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Obsidian Therapeutics.